Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LATITUDE: A phase 3 trial of Cabenuva (cabotegravir and rilpivirine) for the treatment of HIV

Next Previous
Trial Profile

LATITUDE: A phase 3 trial of Cabenuva (cabotegravir and rilpivirine) for the treatment of HIV

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabotegravir+rilpivirine (Primary) ; Bictegravir; Dolutegravir
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LATITUDE

Most Recent Events

  • 06 Mar 2024 According to ViiV Healthcare media release, data from a planned interim analysis of this trial were presented by the advancing clinical therapeutics globally for HIV/AIDS and other infections (ACTG) network at the Retroviruses and Opportunistic Infections (CROI 2024) conference, in Denver, Colorado.
  • 06 Mar 2024 According to ViiV Healthcare media release, This study is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and is being conducted by ACTG, with additional support from the National Institute of Mental Health, the National Institute on Drug Abuse, ViiV Healthcare and the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • 01 Mar 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top